Exosome RNA Exosome RNA Research & Industry News
Inflammation is a double-edged sword. While it plays a crucial role in fighting infections and healing wounds, excessive inflammation can lead to chronic diseases and tissue damage. A key player in this process is the macrophage—a type of immune cell that can shift between a pro-inflammatory (M1) and an anti-inflammatory (M2) state. Controlling this shift is essential for effective tissue repair and disease treatment.
Researchers from Griffith University have developed an innovative method to selectively target M1 macrophages, which are responsible for prolonged inflammation. Their approach utilizes bacteria-derived extracellular vesicles to deliver therapeutic nanoparticles directly to these cells, effectively reducing inflammation without affecting beneficial M2 macrophages.
The M1 macrophage-targeting capability of OMV-decorated gold nanocages (AuNC-OMs) in the 3D dynamic multicellular co-culture system and the application of AuNC-OMs in inflammation control. A) The M1 macrophage-targeting capability of AuNC-OMs. Ligands on AuNC-OMs, including outer membrane protein A (ompA) and LPS, can selectively target receptors highly expressed on M1 macrophages such as CD64 and CD14. B) The M1 macrophage-targeting capability of AuNC-OMs was evaluated in the 3D hydrodynamic multicellular co-culture system. C) The application of AuNC-OM-dex on LPS-induced calvarial bone loss mice model. AuNC-OM-dex can selectively target M1 macrophages in the inflammatory area. Then, AuNC-OM-dex could inhibit inflammation in M1 macrophages by the loaded dex, which was controllably released under near-infrared (NIR) irradiation. At last, AuNC-OM-dex significantly reversed the inflammation and protected the inflammatory calvarial bone resorption.
A “Trojan Horse” Strategy for Drug Delivery
The research team created a hybrid nanoparticle system by combining bacterial outer membrane vesicles (OMVs) with gold nanocages (AuNCs), forming AuNC-OM. These nanoparticles act like a “Trojan Horse”—tricking the immune system into allowing them inside M1 macrophages by mimicking natural bacterial structures. Once inside, they release dexmedetomidine, an anti-inflammatory drug that helps reverse inflammation and prevent tissue damage.
- Selective Targeting: AuNC-OM nanoparticles were selectively absorbed by M1 macrophages without interfering with M2 macrophages.
- Efficient Drug Delivery: The nanoparticles delivered anti-inflammatory drugs directly into inflamed cells.
- Protection Against Bone Loss: In a mouse model, this approach successfully prevented lipopolysaccharide (LPS)-induced bone resorption, a condition associated with excessive inflammation.
This study introduces a promising strategy for treating inflammatory diseases by leveraging extracellular vesicles as precise drug delivery vehicles. The ability to selectively target M1 macrophages while sparing M2 macrophages could lead to more effective therapies for conditions such as arthritis, autoimmune diseases, and chronic inflammation.
